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Artrite enteropática no Brasil: dados do registro brasileiro de 
espondiloartrites
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r e s u m o
As doenças inflamatórias intestinais (doença de Crohn e retocolite ulcerativa) apresentam 
manifestações extraintestinais em um quarto dos pacientes, sendo a mais comum a artrite 
enteropática. 
Métodos: Estudo prospectivo, observacional e multicêntrico, realizado com pacientes de 29 
centros de referência participantes do Registro Brasileiro de Espondiloartrites (RBE), que 
se incorpora ao grupo RESPONDIA (Registro Ibero-americano de Espondiloartrites). Dados 
demográficos e clínicos de 1472 pacientes foram colhidos, e aplicaram-se questionários pa-
dronizados de avaliação de mobilidade axial, de qualidade de vida, de envolvimento entesí-
tico, de atividade de doença e de capacidade funcional. Exames laboratoriais e radiográficos 
foram realizados. Objetivamos, neste presente artigo, comparar as características clínicas, 
epidemiológicas, genéticas, imagenológicas, de tratamento e prognóstico de enteroartríti-
cos com os outros espondiloartríticos nesta grande coorte brasileira. 
Resultados: Foram classificados como enteroartrite 3,2% dos pacientes, sendo que 2,5% ti-
nham espondilite e 0,7%, artrite (predomínio periférico). O subgrupo de indivíduos com en-
teroartrite apresentava maior prevalência de mulheres (P < 0,001), menor incidência de dor 
axial inflamatória (P < 0,001) e de entesite (P = 0,004). O HLA-B27 foi menos frequente no 
grupo de enteroartríticos (P = 0,001), mesmo se considerado apenas aqueles com a forma 
axial pura. Houve menor prevalência de sacroiliíte radiológica (P = 0,009) e também menor 
escore radiográfico (BASRI) (P = 0,006) quando comparado aos pacientes com as demais es-
pondiloartrites. Também fizeram mais uso de corticosteroides (P < 0,001) e sulfassalasina (P < 
0,001) e menor uso de anti-inflamatórios não hormonais (P < 0,001) e metotrexato (P = 0,001).
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a b s t r a c t
Inflammatory bowel diseases (Crohn’s disease and ulcerative rectocolitis) have extraint-
estinal manifestations 25% of the patients, with the most common one being the entero-
pathic arthritis. 
Methods: Prospective, observational, multicenter study with patients from 29 reference cen-
ters participating in the Brazilian Registry of Spondyloarthritis (RBE), which incorporates 
the RESPONDIA (Ibero-American Registry of Spondyloarthritis) group. Demographic and 
clinical data were collected from 1472 patients and standardized questionnaires for the as-
sessment of axial mobility, quality of life, enthesitic involvement, disease activity and func-
tional capacity were applied. Laboratory and radiographic examinations were performed. 
The aim of this study is to compare the clinical, epidemiological, genetic, imaging, treat-
ment and prognosis characteristics of patients with enteropathic arthritis with other types 
of spondyloarthritis in a large Brazilian cohort.
Results: A total of 3.2% of patients were classified as having enteroarthritis, 2.5% had spon-
dylitis and 0.7%, arthritis (peripheral predominance). The subgroup of individuals with en-
teroarthritis had a higher prevalence in women (P < 0.001), lower incidence of inflammatory 
axial pain (P < 0.001) and enthesitis (P = 0.004). HLA-B27 was less frequent in the group 
with enteroarthritis (P = 0.001), even when considering only those with the pure axial form. 
There was a lower prevalence of radiographic sacroiliitis (P = 0.009) and lower radiographic 
score (BASRI) (P = 0.006) when compared to patients with other types of spondyloarthritis. 
They also used more corticosteroids (P < 0.001) and sulfasalazine (P < 0.001) and less non-
steroidal anti-inflammatory drugs (P < 0.001) and methotrexate (P = 0.001).
Conclusion: There were differences between patients with enteroarthritis and other types 
of spondyloarthritis, especially higher prevalence of females, lower frequency of HLA-B27, 
associated with less severe axial involvement.
© 2013 Elsevier Editora Ltda. All rights reserved.
B Universidade Federal do Ceará, Fortaleza, CE, Brasil
C Escola de Medicina e Saúde Pública, Salvador, BA, Brasil
D Universidade Federal do Pará, Belém, PA, Brasil
E Universidade Federal do Espírito Santo, Vitória, ES, Brasil
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Conclusão: Foram encontradas diferenças entre as enteroartrites e as demais espondiloar-
trites, principalmente maior prevalência do sexo feminino, menor frequência do HLA-B27, 
associados a uma menor gravidade do acometimento axial.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Inflammatory bowel disease (IBD) is the term currently used 
to designate two diseases considered idiopathic to date: 
Crohn’s disease (CD) and ulcerative rectocolitis (URC). Al-
though grouped together, the two can be differentiated by 
defined clinical, endoscopic, histological, and etiopathogenic 
characteristics.
Both diseases affect men and women equally and have a 
peak incidence in the second and third decades of life; the 
prevalence of each is estimated at 25-250 per 100,000 individu-
als, with a slight predominance of URC. Their main symptoms 
are diarrhea, abdominal pain, and gastrointestinal bleeding, 
in addition to systemic symptoms such as fever, weight loss, 
and fatigue. They often have an intermittent course, alternat-
ing periods of exacerbation and remission.
CD is characterized by transmural (granulomatous in only 
approximately 30%) and discontinuous inflammation of the 
digestive tract, and it affects mainly the distal small intestine 
(ileum), but with potential to reach any other segment, from 
the mouth to the anus. Due to its tendency to cause fibrosis, it 
can lead to stenosis and obstruction, and because of the pos-
sibility of micro-perforations, fistulas may appear.
URC, in turn, is characterized by a superficial and continu-
ous involvement of the colonic mucosa, almost invariably in-
volving the rectum and sometimes extending proximally. It 
is usually classified (regarding the severity and extent of in-
volvement) as mild when only the rectum or rectosigmoid are 
affected (proctitis or proctosigmoiditis); as moderate, when 
the descending colon is also affected (left colitis); and as se-
vere, when it reaches the cecum (pancolitis). 
Other extraintestinal manifestations can be associated to 
IBD in approximately 25% of patients; the most common are 
those caused by joint (axial or peripheral), eye (uveitis and 
episcleritis), skin (erythema nodosum and pyoderma gan-
grenosum), and biliary tract (sclerosing cholangitis) involve-
ment. These symptoms may precede, coexist with, or follow 
the intestinal manifestations.1-4
Enteroarthritis is the most common extraintestinal mani-
festation of IBD, whose prevalence varies from 14% to 44%.5-8 
It has two main patterns of clinical expression: the peripheral 
and axial forms. The first can be divided into two subgroups: 
type I, which is often self-limited, oligoarticular (< five joints 
involved), accompanies outbreaks of intestinal inflammatory 
activity, and is not associated with the presence of HLA-B27; 
and type II, polyarticular, usually follows an independent 
course from the intestinal disease. The latter rarely becomes 
chronic. The axial form can include sacroiliitis and/or spon-
dylitis unrelated to the bowel disease activity, and may even 
precede its onset by years.9-12 This is associated with the pres-
ence of HLA-B27 in 50% to 75% of cases – a similar frequency, 
although lower, than that found in idiopathic spondylitis.13-15 
There is often some overlapping between these forms, and 
periarticular involvement is possible, whether of the enthe-
ses, tendons, or the periosteum.5,16-18
CARD15 gene polymorphisms have been associated with 
an increased risk of developing CD, and are considered pre-
dictors of both chronic inflammatory bowel disease in pa-
tients with spondyloarthritis and sacroiliitis in those with 
CD. This gene encodes an intracellular protein expressed in 
several cell types, which act as receptor for components of 
bacterial cell wall, and is involved in the activation of nuclear 
factor kappaβ (NF-kβ) and apoptosis.8,19,20 
In this article, the main characteristics of the sample of 
enteropathic arthritis of the Brazilian Registry of Spondylo-
arthritis (Registro Brasileiro de Espondiloartrites – RBE) are 
discussed.
Methods
This was a prospective, observational, multicenter study, con-
ducted with patients from 29 reference centers participating 
in the RBE. All patients met the criteria of the European Spon-
dyloarthropathy Study Group (ESSG).21 Data were collected 
from June 2006 to December 2009. The RBE is a member of 
the Ibero-American Registry of Spondyloarthritis (RESPON-
DIA) group, which consists of nine Latin American countries 
(Argentina, Brazil, Costa Rica, Chile, Ecuador, Mexico, Peru, 
Uruguay, and Venezuela) and the two countries of the Iberian 
Peninsula (Spain and Portugal). 
In this study, a standard protocol was applied to the 1,472 
patients. The diagnosis of enteroarthritis was considered 
when a patient had peripheral or axial inflammatory joint 
involvement associated with CD or URC, diagnosed by a phy-
sician and confirmed by radiographic or endoscopic examina-
tion. 
Demographic and clinical data were collected, and the 
following questionnaires, previously translated and validat-
ed for Brazilian Portuguese) were applied : Bath Ankylosing 
Spondylitis Metrologic Index (BASMI), to assess spinal mobil-
ity;22 Ankylosing Spondylitis Quality of Life (ASQoL), to assess 
quality of life;23 Maastricht Ankylosing Spondylitis enthesitis 
score (MASES), to assess enthesitic involvement;24 Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI), to assess 
disease activity,25 and Bath Ankylosing Spondylitis Functional 
Index (BASFI) to assess functional capacity.26 
Laboratory test results (HLA-B27, erythrocyte sedimen-
tation rate [ESR] and C-reactive protein [CRP]) were also re-
corded, as well as radiographs of the cervical and lumbosacral 
spine and the sacroiliac and coxofemoral joints. Radiological 
damage was evaluated using the Bath Ankylosing Spondylitis 
Radiologic Index (BASRI).27
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Statistical analysis 
Pearson’s chi-squared test was used to analyze the associa-
tion between enteroarthritis and categorical variables, and 
Student’s t-test was used to compare means of numerical 
variables between patients with enteroarthritis and other 
types of spondyloarthritis. An alpha of 5% was used in all 
tests: those with P < 0.05 were considered to be statistically 
significant.
Results
Of a total of 1,472 patients, 65.4% (N = 963) were classified as 
having ankylosing spondylitis (AS), 18.4% (N = 271) as psori-
atic arthritis (PA), 6.7% (N = 98) as undifferentiated spondylo-
arthritis (USpA), 3.3% (N = 49) as reactive arthritis (ReA), and 
3.2% (N = 48) as enteropathic arthritis (EA), with 2.5% (N = 7) of 
spondylitis associated with IBD and 0.7% (N = 11) of arthritis 
associated with IBD. Also, 2.9% were classified as having juve-
nile spondyloarthritis (JSpA) (Fig. 1).
Regarding the clinical forms identified among individu-
als with enteroarthritis, it was observed that the overlapping 
(mixed form, with both axial and peripheral involvement) 
was the most common phenotype with 52.5%, followed by the 
pure axial with 27.5%; isolated peripheral form, with 17.5%; 
and enthesitic form, without axial or peripheral joint involve-
ment, with 2.5% (Fig. 2).
When comparing the clinical characteristics (Table 1) of 
the enteroarthritis group and of other types of spondylo-
arthritis, a statistically significant difference was observed 
regarding the higher frequency of females (P < 0.001) and 
the lower frequency of inflammatory axial pain (P < 0.001) 
and of enthesitis (P = 0.004) in patients with enteropathic 
arthritis.
Patients with enteropathic arthritis showed lower mean 
disease duration (9.6 years vs. 14.1 years, P = 0.005), fewer in-
flamed joints (0.77 vs. 1.61, P = 0.004), as well as better rates 
of mobility in the lumbar spine (mean lateral lumbar flexion 
of 31.5 cm vs. 25.4 cm, P = 0.03; and Schober index of 6.2 cm 
Table 1 – Comparison of demographic and clinical 
characteristics in patients with enteroarthritis and other 
types of spondyloarthritis. 
Brazilian Registry of Spondyloarthritis
Enteroarthritis Spondyloarthritis P
Male gender (N/%) 22/45.8% 1,067/73.2% < 0.001
Age (mean in years) 45.9 42.6 0.100
Time of symptoms 
(mean in years)
9.6 14.1 0.005
Inflammatory axial 
paina (N/%)
33/68.8% 1,286/88.3% < 0.001
Alternating pain in 
buttocks (N/%)
23/47.9% 631/43.3% 0.500
Peripheral arthritis 
(N/%)
23/47.9% 863/59.2% 0.100
Number of inflamed 
joints (mean)
0.77 1.61 0.004
Enthesopathyb (N/%) 14/29.2% 732/50.2% 0.004
Psoriasis (N/%) 6/12.5% 265/18.2% 0.300
Anterior uveitis 
(N/ %)
5/10.4% 296/20.3% 0.092
Positive family 
historyc (N/%)
4/8.3% 245/16.8% 0.100
Lateral lumbar 
flexion (mean; cm)
31.5 25.4 0.030
Schober index 
(mean; cm)
6.2 4.8 0.051
a Lumbar, dorsal or cervical pain comprising at least four of the 
following criteria: insidious, onset before age 45, lasting more than 
three months, improvement with exercise, and morning stiffness.
b Past or present spontaneous pain or at examination of the Achilles 
tendon insertion or plantar fascia.
c Presence in first- or second-degree relatives with one of the 
following: ankylosing spondylitis, psoriasis, acute uveitis, reactive 
arthritis, and inflammatory bowel disease.
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Fig. 2 – Brazilian Registry of Spondyloarthritis - clinical 
forms in enteropathic arthritis.
Fig. 1 – Brazilian Registry of Spondyloarthritis - diagnostic 
distribution.
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vs. 4.8 cm, P = 0.051). No statistical difference was observed 
between the prevalence of extra-articular manifestations, al-
though there was a trend of lower incidence of ocular disease 
(anterior uveitis) in patients with enteroarthritis (10.4% vs. 
20.3% in other types of spondyloarthritis, P = 0.092) (Table 1).
Positivity for HLA-B27 was also statistically significant, 
with a lower frequency in patients with enteroarthritis (p = 
0.001). There was also a statistical difference in CRP measure-
ments between the two groups, with lower values  among 
those with enteropathic arthritis (5.48 mg/L vs. 10.29 mg/L, 
P = 0.001). Conversely, the latter showed a statistical trend to 
higher values  of ESR (31.3 mm vs. 24.7 mm. P = 0.08).  
Regarding radiographic alterations, there was a lower prev-
alence of radiographic sacroiliitis, considering at least grade II 
bilateral or III unilateral (modified New York criteria)28 in in-
dividuals from the enteroarthritis group (60.4% vs. 76.8% P = 
0.009). BASRI scores were also lower, with a mean of 5.2 and 
7.1 in enteroarthritis and other diseases (P = 0.006), respec-
tively and of the BASRI coxofemoral-component (0.6 vs. 1.2; 
P = 0.001).
No statistical differences were observed between the two 
groups regarding professional activity, work disability, exercise 
habits, or ASQoL, BASDAI, BASFI, and MASES scores (Table 2).
As for the therapeutic regimens used (Table 3), a more fre-
quent use of corticosteroids was observed (62.5% vs. 34.6%; P < 
0.001) and less frequent use of nonsteroidal anti-inflammato-
ry drugs (NSAIDs) (43.8% vs. 68.2%; P < 0.001). There was also a 
difference regarding the evaluation of NSAIDs efficacy by pa-
tients. In the enteroarthritis group, only 35.4% of the patients 
described NSAIDs as being effective (i.e., capable of effectively 
improving pain within 48 hours), compared with 69.3% of in-
dividuals with the other diseases (P < 0.001). There is a limita-
tion on the scoring for this comparison, since different drug 
doses and regimens were grouped under the same category. 
Among the disease-modifying antirheumatic drugs 
(DMARDs), there was also a statistical difference between the 
use of methotrexate (with lower use in enteroarthritis, 29.2% 
vs. 52.6%, P = 0.001) and sulfasalazine (with greater use in this 
group, 79.2% vs. 43.2 %, P < 0.001). Among the anticytokine 
agents, infliximab showed only a statistical trend in the fre-
quency of use between the groups (use in the enteroarthritis 
group, 25%, and in other diseases, 15%, P = 0.057). There was no 
difference between the groups regarding the use of other anti-
TNF agents, adalimumab, and etanercept; it is noteworthy that 
the latter drugs were introduced more recently in Brazil.
Discussion
The enteroarthritides, classified within the group of spondy-
loarthritides, have peculiar characteristics that differ in some 
aspects from idiopathic ankylosing spondylitis and other 
diseases in this group. In this study, a small predominance 
of the female gender was observed among patients with en-
teroarthritis, in contrast with other types of spondyloarthri-
tis (where the male/female ratio approaches 3:1). The find-
ings are consistent with the results of studies that found a 
balance5,6,9,29-31 or higher frequency in the female gender,32-34 
although some authors found a male predominance even 
among patients with enteropathic arthritis.8,10,17,35-37
These discrepancies may reflect population differences, 
but above all, they can be related to the fact that some of the 
aforementioned studies did not subdivide their patients into 
more specific groups, such as axial or peripheral involvement, 
or did not consider only patients with enteropathic arthritis, 
but also individuals with inflammatory bowel disease with-
out joint involvement, which in practice greatly diminishes 
the validity of the comparison. 
Regarding the clinical presentation, no significant differ-
ences were observed between the groups with enteropathic 
arthritis and other types of spondyloarthritis. In both groups, 
Table 2 – Comparison of laboratory tests, imaging 
studies and disease rates in patients with 
enteroarthritis and other types of spondyloarthritis. 
Brazilian Registry of Spondyloarthritis
Enteroarthritis Spondyloarthritis P
HLA-B27 10/38.5% 492/70.1% 0.001
CRP (mean; mg/L) 5.49 10.29 0.001
ESR (mean; mm) 31.3 24.7 0.080
BASDAI (mean) 4.62 4.18 0.246
BASFI (mean) 4.77 4.54 0.536
MASES (mean) 1.9 2.1 0.642
High-grade 
radiological 
sacroiliitisa
29/60.4% 1,119/76.8% 0.009
BASRI- column 
(mean)
4.8 5.9 0.055
BASRI- coxofemoral 
(mean)
0.6 1.2 0.001
BASRI-total (mean) 5.2 7.1 0.006
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
a The mere presence of sacroiliitis at plain radiography, graded as at 
least grade II bilateral or unilateral grade III.
Table 3 – Description of the medications used and their 
frequency in patients with enteroarthritis and other 
types of spondyloarthritis.
Brazilian Registry of Spondyloarthritis
Enteroarthritis Spondyloarthritis P
Use of NSAIDs 
(N/%)
21/43.8% 994/68.2% < 0.001
Efficacy of 
NSAIDsa (N/%)
17/37.4% 1,009/69.3% < 0.001
Corticosteroids 
(N/%)
30/62.5% 504/34.6% < 0.001
Methotrexate 
(N/ %)
14/29.2% 766/52.6% 0.001
Sulfasalazine 
(N/ %)
38/79.2% 630/43.2% < 0.001
Infliximab (N/ %) 12/25.0% 218/15.0% 0.057
Etanercept (N/ %) 1/2.1% 43/3.0% 0.725
Adalimumab 
(N/%)
 - /0% 34/2.3% 0.284
NSAIDs, non-steroidal anti-inflammatory drugs.
a The medication was considered effective if it improved pain after 
48 hours of its onset and/or resulted in rapid pain worsening after 
48 hours of withdrawal, regardless of the subclass or dose regimen.
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there was a predominance of mixed form in approximately 
50% of patients, followed by axial and peripheral forms, and 
less frequently, the enthesitic form. These data are similar to 
those found in other studies.17,38,39 
A less severe axial involvement was observed in patients 
with enteroarthritis when compared to individuals with 
other types of spondyloarthritis, verified by the lower prev-
alence of inflammatory axial pain, better rates of mobility 
in the lumbosacral spine, lower frequency of radiographic 
sacroiliitis, and lower BASRI scores (lower radiographic dam-
age). Nevertheless, no difference was observed between 
measures of functional capacity, disease activity and quality 
of life. However, this finding does not necessarily indicate a 
more “benign” nature of IBD-related spondylitis, as it may be 
due to the difference in time of evolution between the two 
groups in this sample (on average, patients with enteropath-
ic arthritis had approximately four years and six months 
less time of symptoms than the others).Some authors have 
found a positive association between the duration of bow-
el disease and the likelihood of developing extraintestinal 
manifestations, reinforcing this hypothesis.9,10,40 A number 
of case series are consistent with the finding of lower radio-
graphic grade in patients with IBD, even in symptomatic ax-
ial disease.29,41,42 In other studies, however, the radiographic 
classification of severity was similar between classical and 
enteropathic spondylitis.43,44 
When comparing the frequency of radiographic sacroili-
itis among patients with enteropathic arthritis in the current 
sample (60%) with several other studies (20% to 61%),17,31,36,37,45 
a high frequency of these alterations was confirmed, even 
without a clear clinical correlation, i.e., no history of pain in 
the buttocks or lumbar region, constituting what some au-
thors call subclinical or asymptomatic sacroiliitis.6,7,40,41,46-49 
Nevertheless, the comparison of these data is possibly flawed, 
given the great variation among the selected populations, im-
aging methods used, the criteria used, and the observers ac-
cording to different studies - many of which were multicenter, 
including the present study. 
This study also found a lower prevalence of HLA-B27 in in-
dividuals with enteroarthritis when compared to other types 
of spondyloarthritis (38.5% vs. 70.1%; P = 0.001), although this 
difference decreases when the subgroup with pure axial in-
volvement (IBD-related spondylitis), in which the presence of 
this antigen reaches 47.6, is analyzed separately. Among those 
classified as having the pure peripheral form that were tested, 
none had it. The results are consistent with those of studies 
that found a higher prevalence of HLA-B27 in patients with 
IBD and axial form than in patients without the axial form 
(albeit at a lower frequency when compared to that found in 
idiopathic ankylosing spondylitis).10,17,35,40,48,50  
However, the population frequency of the allele should 
always be considered when interpreting data on the preva-
lence of genetic markers, which may explain discrepancies 
between different studies with different populations.35,51
Regarding the medications, the lower frequency of use of 
NSAIDs and higher use of corticosteroids have also been ob-
served in other studies,17,50 and probably reflect the fear of ad-
ministering NSAIDs to patients with IBD at risk of exacerba-
tion of bowel symptoms. This risk, however, has no consensus 
regarding its real magnitude.52
In the present study, differences between patients with 
enteroarthritis and other spondyloarthritides were observed, 
especially higher prevalence in females, and lower frequency 
of HLA-B27, even in those with the pure axial form and asso-
ciated with the lower degree of severity of axial involvement. 
These peculiarities should be taken into account when man-
aging patients with IBD and musculoskeletal complaints.
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